Course Details

Course Summary

Cardiopulmonary

Heart disease is the leading cause of death for both men and women in the United States. According to the CDC, in the United States alone there are 7.1 million survivors of myocardial infarction (MI) and 4.9 million people living with congestive heart failure (CHF). The incidence of heart failure leading to hospitalization, and its mortality rates continue to rise. Heart failure therefore remains the main unsolved problem in cardiology. Because homograft transplants are costly, dependent on a scarce donor-organ pool, and vulnerable to complications, they will never be adequate for widespread treatment of end-stage heart failure. Cell and molecular therapies to repair and regenerate the myocardium after myocardial infarction will eliminate the frustrations of contemporary heart failure treatment by creating new contractile units in the damaged heart or even by creating a “cloned heart” from stem cells.  Stem cell therapy and regenerative medicine  is emerging as a multidisciplinary field involving molecular and cell biologists, embryologists, pathologists, clinicians, bioengineers, and ethicists. Clinical study evidence suggests that stem cells derived from adult tissues (especially bone marrow) may develop into myocardial cells. This phenomenon occurs naturally in human beings, specifically during recovery from a myocardial infarction. Cardiac experiments, mainly with adult homologous stem cells, have proved that this therapy is safe and may improve myocardial vascularization and pump function.

Lung diseases remain a significant and devastating cause of morbidity and mortality worldwide. In contrast to many other major diseases, lung diseases notably chronic obstructive pulmonary diseases (COPD), including both asthma and emphysema, are increasing in prevalence and COPD is expected to become the 3rd leading cause of disease mortality worldwide by 2020. For patients in the late stages of lung disease, transplantation is sometimes the only viable therapeutic option. However, organ availability is limited and rejection presents an additional challenge. New therapeutic options are desperately needed. A rapidly growing number of investigations of stem cells and cell therapies in lung biology and diseases as well as in ex vivo lung bioengineering have offered exciting new avenues for advancing knowledge of lung biology as well as providing novel potential therapeutic approaches for lung diseases. These initial observations have led to a growing exploration of endothelial progenitor cells and mesenchymal stem (stromal) cells in clinical trials of pulmonary hypertension and chronic obstructive pulmonary disease (COPD) with other clinical investigations planned.  Lung is thus a ripe organ for a variety of cell therapy and regenerative medicine approaches. Current state-of-the-art progress for each of the above areas will be presented as will discussion of current considerations for cell therapy based clinical trials in lung diseases.


What's Included

Maharaj - Adult Stem Cells - Current Clinical Treatments

This unit is an introduction to adult stem cells and their importance in treatment. 

Quyyumi - Circulating Progenitors as Markers of Risk

This unit will cover cardiovascular risk factors and disease. The prognosis of such disease will be discussed.

Quyyumi - Endothelial Progenitor Cell Therapy in Cardiovascular Diseases

The purpose of this unit is to understand the selection of stem cells for cardiovascular diseases and their therapies.

Quyyumi - The Biology of Endothelial Progenitor Cells

This unit will explain what endothelial cells are. This unit discusses the function of EPCs, identification of EPCs and how EPCs and cardiovascular diseases relate.

Quyyumi - Cell Therapy in Cardiovasculart Diseases Part 1 - Acute MI Studies

The purpose of this unit is to understan various approaches regarding cell therapy for Acute Myocardial Infarctions.

Quyyumi - Cell Therapy in Cardiovasculart Diseases Part 2

The purpose of this unit is to understand various approaches regarding cell therapy for Acute Myocardial Infarctions.

Sueblinvong - Cystic Fibrosis - A Review and Update on Novel Therapies

This unit provides an introduction of Cystic Fibrosis pathophysiology and pathogenesis. It will explain the current standard/approved therapies. It will also cover gene therapy approaches for CF, Cell-based therapy approaches for CF and Pharmacological therapy approaches.

Weiss - Stem Cells, Cell Therapies, and Ex Vivo Lung Bioengineering Approaches for Lung Diseases (1 )

This unit covers stem cell therapies for Lung Diseases. 

Weiss - Bioengineering Approaches for Lung Diseases (Part 2 )

This purpose o this unit is to understand stem cell therapies for Lung Diseases. 

Quyyumi - Cell Therapy in Cardiovascular Diseases - Part 1

The purpose of this unit is to understand various approaches regarding cell therapy for Acute Myocardial Infarctions.

Quyyumi - Cell Therapy in Cardiovascular Diseases - Part 2 - Acute MI Studies

The purpose of this unit is to understand various approaches regarding cell therapy for Acute Myocardial Infarctions.

Quyyumi - Cell Therapy in Cardiovascular Diseases - Part 3

The purpose of this unit is to understanding various approaches regarding cell therapy for Acute Myocardial Infarctions.

Enrollment Cost

Price: 
$1,200.00 (tax incl.)

Course Specifics


Course Title

Cardiopulmonary

Total Lectures

12

Total Units

11

Total Length

00:00:00